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Determination of free urinary cortisol is a test of choice in the diagnosis of Cushing’s syndrome. In this study, cortisol was quantified 
using reversed-phase high-performance liquid chromatography (RP-HPLC) in urine samples previously extracted with ether and using 
triamcinolone acetonide as internal standard (IS). A BDS-Hypersil-C18® column, water-acetonitrile (72:28; v/v), with a flow rate of 
1.0 mL/min and detection at 243 nm were used. This method showed to be both effective and efficient, with sensitivity and linearity 
ranging from 2.50 to 150 µg/L, and can be used in substitution to the radioimmunoassay technique within this concentration range.
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INTRODUCTION
Cortisol (F) determination in the different organic fluids has been 
used as a diagnostic aid in several pathologies as well as in clinical 
research studies. 
Measurements of free F in urine and of F and corticotropin 
(ACTH) in plasma are tests of choice in the diagnosis of Cushing’s 
syndrome. 
Cushing’s syndrome is a hormonal disorder caused by prolonged 
exposure of the body tissues to high levels of the hormone cortisol. 
Sometimes called hypercortisolism, Cushing’s syndrome is relatively 
rare and most commonly affects adults aged 20 to 50 years. People 
who are obese and have type 2 diabetes, along with poorly controlled 
blood glucose and high blood pressure, have an increased risk of 
developing the disorder.1 
Historically, several methods using the radioimmunoassay 
technique (RIA) were developed to determine F. This technique is 
still susceptible to cortisone interference and/or other endogenous 
steroidal metabolites and synthetic glucocorticoids.2 Another limi-
tation of the RIA techniques is the impossibility of using an internal 
standard to monitor the recovery of F in the extraction process. 
Recent reviews comparing RIA with chromatographic methods in 
the determination of F clearly indicate that more accurate results 
are obtained with the latter.3-7 Limitations such as those observed 
using RIA in F determination led to the development of more 
specific methods based on liquid chromatography with ultraviolet 
detection (HPLC-UV),7-11 liquid chromatography combined with 
mass spectrometry (LC-MS)5,7,12 and gas chromatography combi-
ned with mass spectrometry (GC-MS).13-15 LC-MS/MS methods 
are among the most successful approaches to improve specificity 
problems inherent in many immunoassays. The latest generation of 
tandem mass spectrometers has superior limits of quantification, 
permitting omission of previously employed derivatization steps.16,17 
Chromatographic methods have enabled interferent reduction not 
only in the quantification of cortisol, but also of cortisone and 
endogenous F metabolites. 
In this study, a method was developed to quantify free F in urine 
using reversed-phase high-performance liquid chromatography 
(RP-HPLC) after liquid-liquid extraction18,19 and using triamcinolone 
acetonide (T) as internal standard. 
EXPERIMENTAL
Reagents
Cortisol (98%) was provided by Sigma-Aldrich (St. Louis, MO, 
USA) and Triamcinolone acetonide (100%) by USP (Rockville, MD, 
USA). Methanol and acetonitrile were HPLC grade, and ether was 
analytical reagent grade (Merck, Darmstadt, Germany). Water was 
obtained with a Milli-Q purification system (Millipore, Bedford, MA 
USA). Both acetic acid (Merck, Darmstadt, Gemany) and sodium 
hydroxide (Vetec, Rio de Janeiro, Brazil) were used in 10% solutions. 
Standards
Standard solutions (0.01, 0.10, 10.0, and 100 x 101 µg/mL) of F 
and T were prepared in methanol and stored at –20 ºC. Triamcino-
lone acetonide was used as internal standard in the chromatographic 
analyses. 
Sample preparation
Urine samples (5.0 mL) added with T (40.0 ng/mL) were extrac-
ted with ether (3.0 mL) by shaking in Vortex® and then centrifuged 
(2.1130 g, 15 min, 4 ºC). The organic phase was evaporated under a 
nitrogen stream. The residue was resuspended in the mobile phase 
(200 µL), filtered through a membrane (Durapore®, 0.45 µm, 13 mm; 
Millipore, São Paulo, BR) and injected (50.0 µL) onto the chroma-
tographic column.
 Optimal pH for extraction was determined through sample 
recovery tests with a known concentration (50.0 µg/L) of F in acid 
(5.0), neutral (7.0), or alkaline (9.0) pH, adjusted with acetic acid or 
sodium hydroxide. 
RP-HPLC 
A HP 1100 high-performance liquid chromatograph (Hewlett-
Packard, Palo Alto, CA, USA) consisting of an automatic sampler, a 
quaternary pump and variable-wavelength (l=243 nm) UV detector 
was used. Chromatographic separations were accomplished with a 
BDS-Hypersil-C18 analytic column® (250 x 4 mm, 5 µm), with equi-
valent guard-column, obtained from Agilent (USA), and maintained 
at 40 ºC during analysis. Water-acetonitrile (72:28; v/v) was used as 
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mobile phase with a flow rate of 1.0 mL/min for 9.0 min, and 1.5 
mL/min for 6.0 min. At 15.0 min, the mobile phase was changed to 
acetonitrile (100%), which was maintained for 2.0 min. At 17 min, 
the initial condition was reestablished and maintained for another 3 
min, for a new chromatographic run. 
Calibration curve
A calibration curve for F quantification was determined in 
aqueous media by adding methanolic standard solutions of nine 
different concentrations of F (2.50, 5.00, 10.0, 15.0, 25.0, 50.0, 70.0, 
100, and 150 µg/L) and T (40.0 ng/mL). The curve was obtained using 
the experimental data from the graph representing the ratio between 
the peak areas of F and T versus different concentrations. 
Analytical validation
Linearity was evaluated by repeated (n=5) analysis using 
different concentrations in the range from 2.50 to 150 µg/L. The 
relative standard deviation (RSD) was determined for each con-
centration, and the limit of quantification was defined as being 
the lowest concentration with RSD ≤ 10%. Intra-assay precision 
was determined using samples added with different concentrations 
(2.50 to 150 µg/L) and analyzed in replicate (n=5). Inter-assay 
precision was evaluated in different concentrations for two and 
three consecutive days. The method accuracy was assessed by 
analyzing samples (n=5) with known concentrations prepared in 
the laboratory, using calibrated equipment and glassware. The 
results were expressed as percentages. 
The F and T standard solution samples used to determine these 
parameters were prepared with water. Matrix interference was verified 
using urine from healthy individuals added with known concentrations 
of F (5.00, 10.0, 70.0, and 100 µg/L). 
Sampling
The applicability of the method was evaluated by analyzing sam-
ples (n=30) from the laboratory routines of the Steroids Laboratory 
of the Endocrinology Division (Medicine Department of the Federal 
University of São Paulo) and the Hormones and Molecular Genetics 
Laboratory (LIM/42) of the Endocrinology Division (Medical School 
of the University of São Paulo). Urine samples were stored at –20 
ºC until analysis. 
RESULTS AND DISCUSSION
The method used here, RP-HPLC, was shown to be fast and 
efficient for determining free urinary F. The retention times of F and 
T were 7.3 and 14.1 min, respectively. The total time for chromato-
graphic analysis was 20 min. The retention time was consistent with 
or inferior to the times reported in the literature, all superior to 20 
min. 6,8,10 A typical chromatogram is depicted in Figure 1 (B). Ether 
extraction associates simplicity and low cost for RP-HPLC analysis. 
Furthermore, its use in extraction of steroids is frequently mentioned 
in the literature.18-21 No pH interference was observed in extraction 
recovery, once the relationship between F and T was maintained with 
the different pH values (0.91 ± 0.03). Replacing RIA by RP-HPLC 
allows a significant reduction in the total time of analysis, because 
the usually employed RIA methodology requires a minimum of 6 h 
for the incubation step. Moreover, this method confirms the metho-
dology used for determination of serum cortisol22 in the routines of 
the Steroids Laboratory, contributing to laboratory practice and to 
the replacement RIA.
Linearity was observed in the concentration range from 2.50 to 150 
µg/L with a determination coefficient (r2) of 0.9944, which meets the 
expected work range for a Cushing’s syndrome diagnosis. Table 1 shows 
the precision and accuracy values obtained in the analytical validation 
study. The average values for the intra- and inter-assay RSD were 3.2% 
Figure 1. Characteristic analytical chromatogram of urinary free cortisol 
using RP-HPLC. (A) Added to water 25.0 µg/L; (B) original urine sample (# 8); 
and (C) negative control. I.S.: Internal Standard (Triamcionolone Acetonide)
A)
B)
C)
Table 1. Results of analytical validation obtained in the precision and ac-
curacy study
Concentration
(µg/L)
Precision (RSD%) Accuracy
(%)Intra-assay (n=5) Inter-assay
2.50
5.00
10.0
15.0
25.0
50.0
70.0
100
150
3.10
4.20
3.00
3.80
7.70
0.70
1.30
2.70
2.80
ND
3.00 (n=2)
12.7 (n=3)
ND
5.00 (n=2)
ND
1.20 (n=2)
2.70 (n=3)
ND
ND
114
90.6
ND
89.4
ND
88.9
95.9
ND
ND: Not determined
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Table 2. Results of RP-HPLC measurements of free cortisol in urine (24 h), 
serum, and saliva samples of the same patients with an initial suspicion of 
autonomous cortisol secretion not confirmed by the suppression test (1 mg 
dexamethasone) 
Sample
Urinary free  
cortisol
(µg/24 h)
Serum 
cortisol
(µg/dL)
Salivary cortisol
(ng/dL)
8 h 23 h
1 37.1 1.60 66.5 527
2 12.2 2.20 26.6 87.0
3 12.4 2.10 51.0 178
4 20.2 1.90 33.0 156
5 35.7 1.10 92.6 122
6 3.30 2.30 98.7 289
7 16.4 1.10 7.00 212
8 19.7 ND ND ND
9 3.70 ND ND ND
10 41.7 2.00 56.0 181
11 19.8 1.20 7.00 301
12 34.6 1.90 50.0 346
Note: Free urinary cortisol samples #8 and #9 were from the same patients 
as samples #6 and #10, respectively. 
Table 3. Results of free cortisol measurements by RP-HPLC and total cortisol by fluoroimmunoassay in urine samples from patients with confirmed and not 
confirmed diagnosis of autonomous cortisol secretion
Sample Urinary free cortisol (µg/24 h) Total urinary cortisol (µg/24 h) Serum cortisol (µg/dL) Diagnosis
13 863 411 x 101 ND Cushing’s disease
14 96.7 595 ND Cushing’s disease
15 21.3 143 ND Not confirmed
16 65.7 405 19.2 Cushing’s disease
17 204 113 x 101 20.2 Cushing’s disease
18 26.1 18.0 ND Not confirmed
19 136 742 20.5 Ectopic Cushing’s syndrome
20 184 442 21.0 Ectopic Cushing’s syndrome
21 323 380 21.0 Cushing’s disease
22 20.9 312 5.20 Cushing’s disease
23 62.9 608 ND Ectopic Cushing’s syndrome
24 84.4 567 ND Ectopic Cushing’s syndrome
25 81.1 371 17.4 Cushing’s disease
26 15.7 810 16.6 Cushing’s syndrome by adrenal tumor
27 40.5 467 27.8 Ectopic Cushing’s syndrome
28 49.8 570 5.00 Cushing’s syndrome by adrenal tumor
29 111 136 x 101 29.3 Cushing’s disease
30 23.7 332 13.2 Ectopic Cushing’s syndrome
(from 2.50 to 150 µg/L) and 4.6% (from 5.00 to 100 µg/L), respectively. 
These findings were compatible with those reported in the literature for 
the same concentration range, reported to vary around 7.0%.5,6,23 The ac-
curacy of the method is between 88.9 and 114%, which is also compatible 
with the reports of the literature showing values between 88 and 97%.5,24 
The limit of quantification found was 2.50 µg/L. The sensitivity of this 
method was similar or even higher than that of other published methods, 
for which the limit of quantification was 5.0 µg/L.5,10,25,26 
Tables 2 and 3 show the results obtained for samples submitted to 
the RP-HPLC method. In 30 determinations made with samples from 
19 patients, the values ranged between 3.30 and 863 µg/24 h. Regar-
ding the reference value (55.0 µg/24 h), 36.6% of the obtained results 
were suggestive of a Cushing’s syndrome diagnosis. As these samples 
were obtained from patients under clinical evaluation, we were able to 
compare the results with the corresponding diagnoses, confirmed by 
the pathological, imaging, and petrosal sinus catheterism examinations. 
The results of the samples numbered from 1 to 12 (Table 2) were 
evaluated for cortisol in serum and/or saliva and correspond to data 
supplied by the routine laboratory. Cortisol measurement by RIA was 
performed using an adapted laboratory routine.21 The concentration in 
µg/dL was calculated using the RIACALC software (WallacOy) and 
the results were corrected for the initial volume and the dilution of 
the samples. The serum cortisol levels within the clinical application 
interval lied between 2.00 and 25.0 µg/dL27,28, while, according to the 
literature, the morning levels of salivary cortisol in adults are higher 
than 486 ng/dL, and the nocturnal concentrations vary from 36.4 to 
302 ng/dL.29 The samples numbered from 13 to 30 (Table 3) were 
evaluated for cortisol in total urine and, whenever possible, in serum. 
Discrepancy was observed in five (27.8%) evaluations of this group. 
The results obtained were evaluated for efficiency in screening 
for Cushing syndrome by establishing a specific cutoff score, 
as proposed in the literature.30 Thus, values of 100.0 and 69.0% 
were obtained for specificity and sensitivity, respectively; these 
parameters represent the ability of the method to recognize a truly 
negative or positive condition, respectively. Based on a conclusive 
diagnosis of Cushing’s syndrome and using the statistical tool des-
cribed above, we suggested a reference value which is appropriate 
for screening this syndrome by measuring free urinary cortisol. 
The proposed reference value is 50.0 µg/24 h which provides an 
increase of sensitivity to 75% without harming the analytical spe-
cificity. Similarly, a borderline value of 41.0 µg/24 h was found 
for free urinary cortisol. Therefore, results in the range from 41.0 
to 50.0 µg/24 h are suggestive of Cushing’s syndrome, however 
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inconclusive, due to the possibility of false-positive (7%) and 
-negative (19%) results. 
CONCLUSION
A method using RP-HPLC is proposed that was shown to be 
sensitive and specific for the determination of free urinary cortisol, 
with advantages over radioimmunoassay because it does not produce 
radioactive waste and is less time-consuming. The results obtained 
indicate that the proposed methodology can be useful as a diagnos-
tic tool in patients suspected to have Cushing’s syndrome. Further 
studies should be conducted for a better evaluation of the possibility 
of establishing a new reference value. 
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